Loading organizations...
§ Private Profile · Hangzhou, Zhejiang, China
Clinical-stage biopharmaceutical company discovering and developing oncology antibody-drug conjugates (ADCs) for cancer.
BlissBio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oncology biological therapeutics, particularly tumor-targeting antibody-drug conjugates, based in Hangzhou, China. The enterprise operates proprietary technology platforms and an in-house GMP manufacturing facility to support its pipeline of multiple innovative candidates currently advancing through Phase I and Phase II clinical trials. The firm recently received Investigational New Drug approval from the US FDA for its novel BB-1712 therapeutic and will present clinical data at the ESMO Congress and AACR Annual Meeting. BlissBio finances its operations through venture capital rounds, including recent Series B+ and B++ tranches, alongside strategic partnership deals such as a joint development agreement with Eisai Co., Ltd. that includes potential milestone payments of up to $2 billion. The company was founded in 2017 by a team of pharmaceutical veterans.
BlissBio has raised $61.3M across 1 funding round.
BlissBio has raised $61.3M in total across 1 funding round.
BlissBio has raised $61.3M in total across 1 funding round.
BlissBio's investors include Highfields Capital Management, Cormorant Asset Management, Darren Cai, VMS Group.
BlissBio has raised $61.3M across 1 funding round. Most recently, it raised $61.3M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 16, 2021 | $61.3M Series B | Highfields Capital Management | Cormorant Asset Management, Darren CAI, VMS Group | Announced |